LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

Guardant Health Inc

Geschlossen

BrancheGesundheitswesen

63.62 0.46

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

63.15

Max

64.48

Schlüsselkennzahlen

By Trading Economics

Einkommen

-4.7M

-100M

Verkäufe

29M

232M

Gewinnspanne

-43.044

Angestellte

1,999

EBITDA

22M

-89M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

-2.48% downside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

2.2B

7.7B

Vorheriger Eröffnungskurs

63.16

Vorheriger Schlusskurs

63.62

Nachrichtenstimmung

By Acuity

21%

79%

28 / 372 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Guardant Health Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

27. Aug. 2025, 22:51 UTC

Ergebnisse

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27. Aug. 2025, 23:57 UTC

Ergebnisse

Trip.com Group 1H Rev $4.01B

27. Aug. 2025, 23:57 UTC

Ergebnisse

Trip.com Group 1H Adj EPS $1.84

27. Aug. 2025, 23:57 UTC

Ergebnisse

Trip.com Group 1H EPS $1.82

27. Aug. 2025, 23:50 UTC

Market Talk

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27. Aug. 2025, 23:39 UTC

Ergebnisse

Correction to Nvidia Earnings Article -- WSJ

27. Aug. 2025, 22:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. Aug. 2025, 22:59 UTC

Market Talk

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27. Aug. 2025, 22:58 UTC

Ergebnisse

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27. Aug. 2025, 22:57 UTC

Ergebnisse

South32 FY Free Cash Flow $192 Million

27. Aug. 2025, 22:56 UTC

Ergebnisse

South32 FY Total Capital Expenditure $1.35 Billion

27. Aug. 2025, 22:56 UTC

Ergebnisse

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27. Aug. 2025, 22:55 UTC

Ergebnisse

South32 Net Cash $123 Million at June 30

27. Aug. 2025, 22:54 UTC

Ergebnisse

South32: Focused on Maintaining Strong Operating Momentum

27. Aug. 2025, 22:53 UTC

Ergebnisse

South32: $144 Million Remains to be Returned to Shareholders Under Program

27. Aug. 2025, 22:53 UTC

Ergebnisse

South32 Extends Capital Management Program for 12 Months

27. Aug. 2025, 22:52 UTC

Ergebnisse

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27. Aug. 2025, 22:51 UTC

Ergebnisse

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27. Aug. 2025, 22:51 UTC

Ergebnisse

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27. Aug. 2025, 22:50 UTC

Ergebnisse

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27. Aug. 2025, 22:50 UTC

Ergebnisse

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27. Aug. 2025, 22:45 UTC

Ergebnisse

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27. Aug. 2025, 22:44 UTC

Ergebnisse

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27. Aug. 2025, 22:44 UTC

Ergebnisse

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27. Aug. 2025, 22:43 UTC

Ergebnisse

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27. Aug. 2025, 22:43 UTC

Ergebnisse

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27. Aug. 2025, 22:42 UTC

Ergebnisse

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27. Aug. 2025, 22:42 UTC

Ergebnisse

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27. Aug. 2025, 22:40 UTC

Ergebnisse

Sandfire Resources Net Debt $123 Million at June 30

27. Aug. 2025, 22:40 UTC

Ergebnisse

Sandfire Resources FY Underlying Ebitda $527.7 Million

Peer-Vergleich

Kursveränderung

Guardant Health Inc Prognose

Kursziel

By TipRanks

-2.48% Nachteil

12-Monats-Prognose

Durchschnitt 61.86 USD  -2.48%

Hoch 70 USD

Tief 56 USD

Basierend auf 16 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Guardant Health Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

16 ratings

16

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

38.86 / 47.41Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

28 / 372 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.